Active surveillance is an important option to reduce prostate cancer overtreatment, but it remains underutilized in many countries. Models from the United States show that greater use of active surveillance is important for prostate cancer screening to be cost-effective.
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Supplemental content L ow-risk prostate cancer has a prolonged natural history and can be safely managed with active surveillance and selective, deferred use of curative treatment. Despite this, recent US studies have reported that most low-risk prostate cancer is managed with immediate curative treatment, 1 often reducing quality of life. Moreover, a recent modeling study showed that prostate cancer screening is generally not cost-effective based on current US treatment patterns but would be cost-effective if low-risk prostate cancer were managed conservatively. 2 Although Sweden does not have a national screening program, more than 50% of Swedish men aged 55 to 69 years have been exposed to prostate-specific antigen (PSA) screening. 3, 4 Our group previously reported increasing use of active surveillance in Sweden through 2011. 5 The goal of the present study is to perform an updated analysis of nationwide use of active surveillance using comprehensive, population-based Swedish data through 2014.
Methods
The National Prostate Cancer Register (NPCR) includes 98% of all prostate cancer cases in Sweden. 6, 7 Designated staff at each health care unit extract data on cancer features and treatment from the medical records to an online registration in NPCR and have distinguished "watchful waiting" from "active surveillance" since 2007. In addition, the Longitudinal Integration Database for Health Insurance and Labor Market Studies provided socioeconomic data, and the Patient Register provided information on comorbidities.
7
The Umeå University Research Ethics Board approved the study, waiving patient written informed consent.
Descriptive statistics and the Mann-Kendall test for trend based on the Kendall rank correlation were used to examine active surveillance utilization from 2009 
Results
Between 2009 and 2014, 32 518 men, median age of 67 years, were diagnosed with favorable-risk prostate cancer (Table) . Use of active surveillance and watchful waiting increased from 64% to 93% for very-low-risk disease, 50% to 79% for low-risk disease, and decreased from 26% to 25% for intermediate-risk cancer from 2009 to 2014. Use of active surveillance increased from 57% to 91% for very-low-risk cancer and from 40% to 74% for low-risk cancer (P < .001 for all comparisons), whereas use of watchful waiting decreased over time ( Figure) . The greatest increase in active surveillance for very-low-risk and low-risk cancer occurred after 2011. Classifying men using CAPRA scores, we found that active surveillance increased from 17% to 62% in men with CAPRA 0, 50% to 85% in CAPRA 1, 33% to 55% in CAPRA 2, and 22% to 29% in CAPRA 3. In men with CAPRA scores higher than 3, use of active surveillance was relatively stable (eFigure 1 in the Supplement). Active surveillance increased over time in all age groups (<60, 60-69, and ≥70 years) (Figure) . In men with very-lowrisk cancer, active surveillance increased from 44% to 88% in those aged 50 to 59, from 64% to 95% in those aged 60 to 69 years, and from 53% to 84% in those aged 70 years or older. In men with low-risk disease, active surveillance also increased, from 30% to 68% among those aged 50 to 59 years, from 43% to 79% in those aged 60 to 69 years, and from 44% to 67% in those aged 70 years or older. Even among men younger than 50 years, active surveillance increased, to 89% and 43% among men with very-low-risk and low-risk disease by 2014. Using the Epstein and PRIAS criteria for active surveillance yielded almost identical results, 93% and 90%, respectively, compared with 91% by the NPCR very-low-risk definition (eFigure 2 in the Supplement).
Active surveillance use among men in the intermediaterisk category remained low during the entire study period. However, use of active surveillance increased from 31% in 2009 to 53% in 2014 in the intermediate-risk subset with Gleason, 6 and PSA, 10 to 20 ng/mL. Use of active surveillance remained low in those with Gleason, 7 (3 + 4) and PSA, less than 10 ng/mL (17% in 2014) (eFigure 3 in the Supplement).
Within each clinical risk category, later year of diagnosis, diagnosis at a university hospital, older age, and status of not currently married were associated with the use of active surveillance, while comorbidity and educational level were not associated. 
Discussion
This population-based study shows the highest uptake of active surveillance ever reported: by 2014, 91% of Swedish men diagnosed with very-low-risk prostate cancer and 74% with low-risk disease initiated active surveillance. This use of active surveillance is substantially higher than that reported in the United States. 1,9,10 Potential facilitating factors for the rapid uptake of active surveillance in Sweden include 2007 national guidelines recommending active surveillance for men with low-risk prostate cancer and a life expectancy of 10 to 20 years. In 2014, the 20-year upper limit for life expectancy was abandoned, and active surveillance was recommended for all men with very-low-risk prostate cancer. Importantly, NPCR provides real-time feedback to units on their adherence to these national guidelines and also in annual reports publicly available online. 11, 12 The creation in 2010 of 6 regional cancer networks, supporting cancer services from primary to tertiary care, likely also increased adherence to the guidelines. The Swedish health care system is dominated by equal-access, taxfunded care without financial incentives for clinicians to recommend curative treatment. Furthermore, there may also be cultural differences in attitudes toward conservative management between Sweden and other countries such as the United States with lower use of these strategies. However, use of conservative management in the United States also rapidly increased from 2010 through 2013, suggesting more widespread acceptance worldwide.
A limitation of our study is that the interpretation of the definition of active surveillance among some clinicians became less stringent for men 70 years or older, indicated by the fact that more than twice as many men younger than 70 years on active surveillance underwent a repeat biopsy compared with men 70 years or older (eTable in the Supplement).
Another limitation is that our study does not include follow-up data on active surveillance outcomes. However, the objective was to study initial treatment selection by contemporary cases, and our group previously demonstrated that the majority of Swedish men on active surveillance had not converted to curative treatment at 5 years.
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A strength of our study is that, unlike data from US registries that do not differentiate active surveillance from watchful waiting or low-risk from very-low-risk prostate cancer, 1, 9 the Swedish NPCR provides population-based data on all of these features, and in addition, provides information on potential confounders including socioeconomic status and comorbidity from other nationwide databases. To our knowledge, there are no other reports from Europe on nationwide active surveillance use except our group's earlier Swedish data.
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Conclusions
In summary, active surveillance can preserve the benefits of screening while minimizing harm caused by overtreatment of indolent cancer. 2 The Göteborg randomized prostate cancer screening trial 14 showed the highest mortality reduction ever reported (44%) in a population in which almost half the screendetected cancers were managed with active surveillance. 14 Our results show that treatment patterns can be changed on a national level within a few years. Active surveillance is now the dominant management strategy for low-risk prostate cancer across Sweden, and there is an almost complete uptake of active surveillance for very-low-risk cancer. These findings should encourage clinicians, health care authorities, and cancer network administrators in other countries to reduce the harms of screening by minimizing overtreatment of low-risk prostate cancer. 
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